Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast
October 22, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
Webcast scheduled for Monday, November 5th at 4:30 p.m. Eastern Time BOSTON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.,...
Akcea Announces Changes to Board of Directors
October 08, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors The change enhances focus on global approval and commercialization of TEGSEDI™ (inotersen) BOSTON, Oct. 08, 2018 (GLOBE...
Akcea e Ionis anuncian la aprobación de TEGSEDI™ (inyección de inotersén) en Canadá
October 06, 2018 04:31 ET
|
Akcea Therapeutics, Inc.
OTTAWA, BOSTON y CARLSBAD, California, Oct. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc. (NASDAQ:AKCA), una filial de Ionis Pharmaceuticals, Inc. e Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)...
Akcea e Ionis annunciano l'Approvazione di TEGSEDI™ (inotersen iniezione) in Canada.
October 06, 2018 04:31 ET
|
Akcea Therapeutics, Inc.
Ottawa e Boston e CARLSBAD, California, Oct. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), affiliata di Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals, Inc. (NASDAQ:...
Akcea und Ionis geben die Zulassung von TEGSEDI™ (Inotersen-Injektion) in Kanada bekannt
October 06, 2018 04:31 ET
|
Akcea Therapeutics, Inc.
OTTAWA und BOSTON und CARLSBAD, Kalifornien, Oct. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), ein mit Ionis Pharmaceuticals, Inc. verbundenes Unternehmen, und Ionis...
Akcea et Ionis annoncent l’homologation de TEGSEDIMC (inotersen pour injection) au Canada
October 06, 2018 04:31 ET
|
Akcea Therapeutics, Inc.
OTTAWA et BOSTON et CARLSBAD, Californie, 06 oct. 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ : AKCA), une société affiliée d’Ionis Pharmaceuticals, Inc., et Ionis Pharmaceuticals,...
Akcea en Ionis kondigen goedkeuring aan van TEGSEDI™ (inotersen injectie) in Canada
October 06, 2018 04:31 ET
|
Akcea Therapeutics, Inc.
OTTAWA en BOSTON en CARLSBAD, Calif., Oct. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc. (NASDAQ: AKCA), een gelieerde onderneming van Ionis Pharmaceuticals, Inc., en Ionis Pharmaceuticals,...
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)
October 05, 2018 17:33 ET
|
Akcea Therapeutics, Inc.
BOSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), announced today that they are working together with...
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
October 05, 2018 17:32 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life TEGSEDI is an effective treatment choice that allows...
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
October 04, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....